These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 31298334)
1. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19. Wang Y; Lian YM; Ge CY Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334 [TBL] [Abstract][Full Text] [Related]
2. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells. Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967 [TBL] [Abstract][Full Text] [Related]
3. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3. Qi MM; Ge F; Chen XJ; Tang C; Ma J Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375 [TBL] [Abstract][Full Text] [Related]
4. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1. Jin S; He J; Li J; Guo R; Shu Y; Liu P Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988 [TBL] [Abstract][Full Text] [Related]
6. MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19. Shan N; Shen L; Wang J; He D; Duan C Biochem Biophys Res Commun; 2015 Jan; 456(1):385-91. PubMed ID: 25475731 [TBL] [Abstract][Full Text] [Related]
7. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Xiao XH; He SY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431 [TBL] [Abstract][Full Text] [Related]
8. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621. Chen ZY; Liu HY; Jiang N; Yuan JM Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663 [TBL] [Abstract][Full Text] [Related]
9. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5. Li Q; Wang Y; He J J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242 [TBL] [Abstract][Full Text] [Related]
10. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line. Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion. Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927 [TBL] [Abstract][Full Text] [Related]
12. MiR-411-5p acts as a tumor suppressor in non-small cell lung cancer through targeting PUM1. Xia LH; Yan QH; Sun QD; Gao YP Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5546-5553. PubMed ID: 30229827 [TBL] [Abstract][Full Text] [Related]
13. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. Gong J; He L; Ma J; Zhang J; Wang L; Wang J J BUON; 2017; 22(2):454-461. PubMed ID: 28534369 [TBL] [Abstract][Full Text] [Related]
14. PPARĪ± agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARĪ±/AMPK/AKT/FoxO1 pathway. Wang MS; Han QS; Jia ZR; Chen CS; Qiao C; Liu QQ; Zhang YM; Wang KW; Wang J; Xiao K; Ding XS Acta Pharmacol Sin; 2022 Jan; 43(1):167-176. PubMed ID: 33772142 [TBL] [Abstract][Full Text] [Related]
15. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454 [TBL] [Abstract][Full Text] [Related]
16. [Mechanism of miR-221 contributes to gefitinib resistance in PC-9 cells]. Gao YY; Kang XH; Wang Y; Zhao KL; Wang YN; Kou WZ; Miao ZH; Lu P Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(42):3447-3452. PubMed ID: 30440142 [No Abstract] [Full Text] [Related]
17. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974 [TBL] [Abstract][Full Text] [Related]
18. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells. Fan D; Yang Y; Zhang W BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416 [TBL] [Abstract][Full Text] [Related]
19. MiR-645 promotes proliferation and migration of non-small cell lung cancer cells by targeting TP53I11. Zhu B; Tian T; Zhao M Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6150-6156. PubMed ID: 32572880 [TBL] [Abstract][Full Text] [Related]
20. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance. Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]